Evidence map›Paper›PMID 36702363›Full record

ArticleSteroids2023

Murine toxicology and pharmacokinetics of lead next generation galeterone analog, VNPP433-3β.

Elizabeth Thomas, Retheesh S Thankan, Puranik Purushottamachar, Jianxia Guo, Robert A Parise, Jan H Beumer, Vincent C O Njar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Steroids, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Elizabeth ThomasDepartment of Pharmacology, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA; The Center for Biomolecular Therapeutics, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA.
Retheesh S ThankanDepartment of Pharmacology, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA; The Center for Biomolecular Therapeutics, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA; Isoprene Pharmaceuticals, Inc., 801 W. Baltimore Street, Suite 502J, Baltimore, MD 21201, USA.
Puranik PurushottamacharDepartment of Pharmacology, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA; The Center for Biomolecular Therapeutics, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA.
Jianxia GuoCancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA 15213, USA.
Robert A PariseCancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA 15213, USA.
Jan H BeumerCancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA 15213, USA; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, PA 15261, USA; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. Electronic address: beumerjh@upmc.edu.
Vincent C O NjarDepartment of Pharmacology, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA; The Center for Biomolecular Therapeutics, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA; Isoprene Pharmaceuticals, Inc., 801 W. Baltimore Street, Suite 502J, Baltimore, MD 21201, USA; Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA. Electronic address: VNjar@som.umaryland.edu.

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD · 1988 to 2026
$158.0M
PITT-CAL ETCTN PK Resource LaboratoryU24CA247643 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI TIMOTHY W SYNOLD, Raman Venkataramanan · 2020 to 2026
$3.6M
Development of Next Generation Galeterone Analogs for Prostate Cancer TherapyR01CA224696 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI NJAR, VINCENT COLLINS OFUKA · 2018 to 2022
$2.6M
Cancer Pharmacokinetics Research SpecialistR50CA211241 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PARISE, ROBERT · 2016 to 2025
$1.8M
NCI NIH HHS P30 CA047904NCI NIH HHS R01 CA224696NCI NIH HHS R50 CA211241NCI NIH HHS U24 CA247643
6 · The paper itself

Abstract

VNPP433-3β (compound 2, (3β-(1H-imidazole-1-yl)-17-(1H-benzimidazole-1-yl)-androsta-5,16-diene), a multitarget anticancer agent has emerged as our lead next generation galeterone analogs (NGGA). Compound 2 is currently in development as potential new therapeutic for prostate and pancreatic cancers. The preliminary toxicity study reveals that the compound 2 was better tolerated by the normal male CD-1 mice than the male Nude mice. The maximum tolerated dose (MTD) in the Nude mice was estimated to be between 25 < 50 mg/kg. After oral dosing of compound 2 to male and female rats, the plasma concentration versus time curves were very consistent between animals and the AUC

Indexed as

Antineoplastic AgentsAndrostadienesAnimalsBenzimidazolesFemaleMaleMiceMice, NudeRats3-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-dieneAndrostadienesAntineoplastic AgentsBenzimidazolesAnti-prostate cancer agentOral bioavailabilityPharmacokineticsToxicologyVNPP433-3β (2)

Identifiers

PMID36702363
PMCPMC9998351

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.